BONESUPPORT’S CERAMENT G Used in First U.S. Patient Cases

Doctors have used BONESUPPORT’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) for the first time in U.S. patients. Those treated suffered from a bone infection (osteomyelitis) caused by fractures induced by trauma.
 
“CERAMENT G is truly changing the way we can treat osteomyelitis by more directly and effectively addressing the site of the infection in a single stage, patient friendly surgical approach. CERAMENT G has been widely used with great success in other parts of the world and I’m pleased to integrate it in my clinical practice,” said Janet D. Conway, M.D., FAAOS, a board-certified orthopedic surgeon and head of Bone and Joint Infection at Sinai Hospital of Baltimore, who carried out the first surgeries using CERAMENT G in the United States.
 
BONESUPPORT received authorization for CERAMENT G in managing osteomyelitis from the U.S. Food and Drug Administration (FDA) earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3% to 5.5% versus 13.3% for the current U.S. standard of care, PMMA-beads. CERAMENT G is the first and only FDA authorized combination antibiotic-eluting bone graft.
 
BONESUPPORT develops and commercializes injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.